![Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK562120/bin/493434_1_En_1_Fig3_HTML.jpg)
Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf
![Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d25485f8-32b5-4674-a765-bf3c6c55a6f0/fx1.jpg)
Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer
![Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen ... Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/877ea30f-a5f1-4ae9-b000-f4d2174f1dde/gr1_lrg.jpg)
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen ...
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/36478a24-f62d-4c3f-bdbe-2fb076234186/gr1_lrg.jpg)
Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer - European Journal of Surgical Oncology
![A New Nomogram for Predicting Overall Survival and Assisting Postoperative Adjuvant Treatment Decision-Making in Stage II Oral Tongue Squamous Cell Carcinoma: A Surveillance, Epidemiology and End Results (SEER) Database Analysis - Journal A New Nomogram for Predicting Overall Survival and Assisting Postoperative Adjuvant Treatment Decision-Making in Stage II Oral Tongue Squamous Cell Carcinoma: A Surveillance, Epidemiology and End Results (SEER) Database Analysis - Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/31a3b94d-1b93-43cb-b290-3a3e3e0f2614/gr1_lrg.jpg)
A New Nomogram for Predicting Overall Survival and Assisting Postoperative Adjuvant Treatment Decision-Making in Stage II Oral Tongue Squamous Cell Carcinoma: A Surveillance, Epidemiology and End Results (SEER) Database Analysis - Journal
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/356259194/figure/fig2/AS:1091002400022593@1637126650745/Overall-survival-plot-Kaplan-Meier-curve-is-shown-for-overall-survival-in-patients-with.png)
Overall survival plot. Kaplan–Meier curve is shown for overall survival... | Download Scientific Diagram
![Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis](https://jcancer.org/v09/p3156/jcav09p3156g005.jpg)
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis
![Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Journal of Hepatology Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3d9a132c-edbc-440e-a663-6fb023ee8a6a/fx1_lrg.jpg)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Journal of Hepatology
![Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.,British Journal of Cancer - X-MOL Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.,British Journal of Cancer - X-MOL](https://xpic.x-mol.com/20190126%2F10.1038_s41416-018-0360-y.jpg)
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.,British Journal of Cancer - X-MOL
![Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/777aed96-2700-46bf-9ad6-0c159601b8bf/gr1a.jpg)
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
![JCI Insight - Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status JCI Insight - Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status](https://df6sxcketz7bb.cloudfront.net/manuscripts/123000/123443/medium/jci.insight.123443.f2.jpg)
JCI Insight - Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status
![A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/0fbe43e7-b69c-43d2-bff9-10ce650542f3/gr1.jpg)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
![Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ad9b540e-d891-4d45-a088-67c7de8c0dd8/gr1_lrg.jpg)
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) - Annals of Oncology
![Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f202d504-2f19-493f-b3f6-b0e9f416627d/gr1.jpg)
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell
![Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis](https://jcancer.org/v09/p3156/jcav09p3156g008.jpg)
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis
![Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer - Journal of Thoracic Oncology Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040423073/2053914276/gr1.jpg)